Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OST159
MIFTS: 59

Osteogenic Sarcoma

Categories: Genetic diseases, Rare diseases, Bone diseases, Cancer diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Osteogenic Sarcoma

About this section

MalaCards integrated aliases for Osteogenic Sarcoma:

Name: Osteogenic Sarcoma 57 12 76 53 59 75
Osteosarcoma 57 12 53 59 75 37 29 13 55 6 44 15 40 73
Neoplasms, Bone Tissue 44 73
Osrc 57 75
Osteosarcoma, Somatic 57
Bone Tissue Neoplasm 12
Osteosarcoma of Bone 73
Osteosarcoma; Osrc 57
Skeletal Sarcoma 12
Osteoid Sarcoma 12
Bone Sarcoma 73

Characteristics:

Orphanet epidemiological data:

59
osteosarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;

OMIM:

57
Inheritance:
? autosomal recessive


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare bone diseases


External Ids:

OMIM 57 259500
Disease Ontology 12 DOID:3347
NCIt 50 C9145
Orphanet 59 ORPHA668
MESH via Orphanet 45 D012516
ICD10 via Orphanet 34 C41.9
UMLS via Orphanet 74 C0029463
MedGen 42 C0029463
KEGG 37 H00036
Sources

Summaries for Osteogenic Sarcoma

About this section
NIH Rare Diseases : 53 Osteosarcoma is the most common type of bone cancer. The average age at diagnosis is 15. Boys and girls have a similar incidence of this tumor until late adolescence, at which time boys are more commonly affected. In rare cases, osteosarcoma occurs in adults. Although osteosarcoma tends to occur in the larger bones, such as the shin (near the knee), thigh (near the knee) and upper arm (near the shoulder), it can occur in any bone.A number of variants of osteosarcoma exist, including conventional types (osteoblastic, chondroblastic, and fibroblastic), telangiectatic, multifocal, parosteal, and periosteal. The cause of osteosarcoma is not known. In some cases, it runs in families, and at least one gene has been linked to increased risk. Treatment varies from person to person and may include surgery, chemotherapy, radiation therapy, and samarium.

MalaCards based summary : Osteogenic Sarcoma, also known as osteosarcoma, is related to retinoblastoma and glioma. An important gene associated with Osteogenic Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are BRCA1 Pathway and Integrated Cancer Pathway. The drugs Fusilev and Dalteparin have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and lung, and related phenotypes are fever and joint swelling

UniProtKB/Swiss-Prot : 75 Osteogenic sarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones.

Disease Ontology : 12 A bone cancer that is located in bone that has material basis in cells of mesenchymal origin.

Wikipedia : 76 An osteosarcoma (OS) or osteogenic sarcoma (OGS) is a cancerous tumor in a bone. Specifically, it is an... more...

Description from OMIM: 259500
Sources

Related Diseases for Osteogenic Sarcoma

About this section

Diseases related to Osteogenic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 retinoblastoma 30.9 HOTAIR MALAT1 RB1 TP53
2 glioma 30.8 HOTAIR MALAT1 MIR140 NEAT1 TP53 UCA1
3 squamous cell carcinoma 30.6 HOTAIR MALAT1 NEAT1 RB1 TP53 TUG1
4 multifocal osteogenic sarcoma 12.2
5 telangiectatic osteogenic sarcoma 12.2
6 periosteal osteogenic sarcoma 12.2
7 small cell osteogenic sarcoma 12.2
8 synchronous multifocal osteogenic sarcoma 12.2
9 intracortical osteogenic sarcoma 12.1
10 adult extraosseous osteosarcoma 12.1
11 kidney osteogenic sarcoma 12.1
12 bone osteosarcoma 12.1
13 childhood parosteal osteogenic sarcoma 12.0
14 mediastinal osteogenic sarcoma 12.0
15 hepatic osteogenic sarcoma 12.0
16 asynchronous multifocal osteogenic sarcoma 12.0
17 vulvar adenocarcinoma 11.2 RB1 TP53
18 triple-receptor negative breast cancer 11.1 HOTAIR MALAT1
19 li-fraumeni syndrome 2 11.1 CHEK2 TP53
20 localized osteosarcoma 11.0
21 extraosseous osteosarcoma 11.0
22 chondroblastic osteosarcoma 11.0
23 juxtacortical osteosarcoma 11.0
24 fibrosarcomatous osteosarcoma 11.0
25 breast osteosarcoma 11.0
26 ovarian epithelial cancer 11.0 HOTAIR MALAT1 MIR140
27 esophagus squamous cell carcinoma 10.9 HOTAIR TUG1
28 pancreatic ductal adenocarcinoma 10.9 HOTAIR MALAT1 TUSC7 UCA1
29 bladder urothelial carcinoma 10.9 HOTAIR MALAT1 RB1 TP53 TUG1
30 small cell cancer of the lung 10.9 HOTAIR MALAT1 RB1 TP53 TUG1
31 gastrointestinal system cancer 10.9 HOTAIR MALAT1 TP53
32 sarcoma 10.9
33 thyroid cancer, nonmedullary, 1 10.9 HOTAIR MALAT1 NEAT1 SNHG12
34 vulva squamous cell carcinoma 10.9 MALAT1 TP53
35 b-cell lymphomas 10.9 HOTAIR MALAT1 TP53 TUG1
36 myeloma, multiple 10.8 HOTAIR MALAT1 TP53 TUG1 UCA1
37 lung cancer susceptibility 3 10.8 FENDRR HOTAIR MALAT1 TP53 TUG1
38 tongue squamous cell carcinoma 10.8 MALAT1 TP53 UCA1
39 glioblastoma 10.8 HOTAIR MALAT1 RB1 TP53 TUG1 TUSC7
40 cholangiocarcinoma 10.8 MALAT1 NEAT1 TP53 TUG1 UCA1
41 esophageal cancer 10.8 CHEK2 HOTAIR MALAT1 RB1 TP53 UCA1
42 gallbladder cancer 10.8 FENDRR HOTAIR MALAT1 TP53 TUG1 UCA1
43 oral squamous cell carcinoma 10.8 HOTAIR MALAT1 MIR140 NEAT1 TUG1 UCA1
44 leukemia, acute myeloid 10.8 HOTAIR MALAT1 TP53 TUG1 TUSC7 UCA1
45 renal cell carcinoma, nonpapillary 10.8 DANCR HOTAIR MALAT1 TUG1 UCA1
46 schneiderian carcinoma 10.8 SOX4 TP53
47 thyroid cancer 10.7 HOTAIR MALAT1 NEAT1 TP53 UCA1
48 melanoma 10.7 HOTAIR MALAT1 MIR140 TP53 UCA1
49 bladder cancer 10.7 HOTAIR MALAT1 RB1 TP53 TUG1 UCA1
50 adamantinoma of long bones 10.7 HOTAIR MALAT1 NEAT1 RB1 TP53 TUG1

Graphical network of the top 20 diseases related to Osteogenic Sarcoma:



Diseases related to Osteogenic Sarcoma
Sources

Symptoms & Phenotypes for Osteogenic Sarcoma

About this section

Symptoms via clinical synopsis from OMIM:

57
Lab:
osteogenic sarcoma
high alkaline phoshphatase
rearrangements involving chromosomes 13 and 14
loss of heterozygosity of chromosomes 13 and 17

Misc:
increased incidence in retinoblastoma cases
peak freqency in adolescence

Skel:
painful tender mass at long bone metaphysis

Radiology:
bone destruction and mineralized soft tissue mass


Clinical features from OMIM:

259500

Human phenotypes related to Osteogenic Sarcoma:

59 32 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 very rare (1%) Very rare (<4-1%) HP:0001945
2 joint swelling 59 32 frequent (33%) Frequent (79-30%) HP:0001386
3 weight loss 59 32 very rare (1%) Very rare (<4-1%) HP:0001824
4 pathologic fracture 59 32 very rare (1%) Very rare (<4-1%) HP:0002756
5 pain 59 32 frequent (33%) Frequent (79-30%) HP:0012531
6 abnormal lactate dehydrogenase activity 59 32 frequent (33%) Frequent (79-30%) HP:0045040
7 osteolysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002797
8 elevated alkaline phosphatase 59 32 frequent (33%) Frequent (79-30%) HP:0003155
9 abnormality of the femoral metaphysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0006489
10 abnormality of the tibial metaphysis 59 32 frequent (33%) Frequent (79-30%) HP:0006491
11 abnormality of metabolism/homeostasis 32 HP:0001939
12 abnormality of the metaphysis 59 Frequent (79-30%)
13 retinoblastoma 32 HP:0009919
14 osteosarcoma 32 HP:0002669
Sources

Drugs & Therapeutics for Osteogenic Sarcoma

About this section

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008

Drugs for Osteogenic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4,Not Applicable 9005-49-6
2
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Enoxaparin Approved Phase 4 9005-49-6 772
5 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Central Nervous System Depressants Phase 4,Phase 3,Phase 1
12 Cyclooxygenase Inhibitors Phase 4,Phase 2,Not Applicable
13 Antidepressive Agents Phase 4
14 Antimanic Agents Phase 4,Phase 1
15 Lithium carbonate Phase 4 554-13-2
16 Psychotropic Drugs Phase 4,Phase 1
17 Tranquilizing Agents Phase 4,Phase 1
18 Anticoagulants Phase 4,Not Applicable
19 calcium heparin Phase 4,Not Applicable
20 Fibrinolytic Agents Phase 4,Not Applicable
21 Heparin, Low-Molecular-Weight Phase 4,Not Applicable
22 Antipyretics Phase 4
23 Platelet Aggregation Inhibitors Phase 4
24
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
25
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
26
Ifosfamide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 3778-73-2 3690
27
Zoledronic acid Approved Phase 2, Phase 3,Phase 3,Phase 1 118072-93-8 68740
28
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 50-02-2 5743
29
Diphenhydramine Approved, Investigational Phase 2, Phase 3 147-24-0, 58-73-1 3100
30
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
31
Gemcitabine Approved Phase 2, Phase 3,Phase 1,Not Applicable 95058-81-4 60750
32
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
33
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
34
Dactinomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 50-76-0 2019 457193
35
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
36
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
37
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
38
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
39
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
40
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
41
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
42
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
44
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
45
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
46
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 1 284461-73-0 216239 406563
47
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
48
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
49 Mifamurtide Approved, Experimental Phase 2, Phase 3 838853-48-8
50
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700

Interventional clinical trials:

(show top 50) (show all 439)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
2 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
3 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
4 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
5 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
7 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3 pre-surgical chemotherapy
8 Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy Completed NCT02711007 Phase 2, Phase 3 apatinib
9 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3 Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
10 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3 High Dose Methotrexate
11 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
12 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
13 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
14 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
15 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
19 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
20 ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma Recruiting NCT01459484 Phase 2, Phase 3 Mifamurtide arm
21 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
22 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
23 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Recruiting NCT01091883 Phase 3
24 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
25 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
26 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
27 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
28 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
29 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
30 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide;ifosfamide;etoposide;topotecan hydrochloride
31 Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Not yet recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
32 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma Terminated NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
33 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
34 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
35 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
36 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
37 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
38 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma Unknown status NCT01216826 Phase 2 Everolimus
39 A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma Unknown status NCT01002092 Phase 2 Chemotherapy;Endostar
40 Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma Unknown status NCT00689195 Phase 1, Phase 2
41 Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity Unknown status NCT02273583 Phase 2 continuous oral cyclophosphamide and methotrexate
42 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
43 Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
44 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
45 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Unknown status NCT01692496 Phase 2 Pazopanib
46 The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells Unknown status NCT01868490 Phase 1, Phase 2 cytokine induced killer cells
47 Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Unknown status NCT01696669 Phase 2 Chemotherapy
48 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
49 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
50 Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma Completed NCT02429973 Phase 2 Gemcitabine plus rapamycin

Search NIH Clinical Center for Osteogenic Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: osteosarcoma

Sources

Genetic Tests for Osteogenic Sarcoma

About this section

Genetic tests related to Osteogenic Sarcoma:

# Genetic test Affiliating Genes
1 Osteosarcoma 29 CHEK2 RB1 TP53
Sources

Anatomical Context for Osteogenic Sarcoma

About this section

MalaCards organs/tissues related to Osteogenic Sarcoma:

41
Bone, T Cells, Lung, Testes, Brain, Nk Cells, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Osteogenic Sarcoma:

19
Bone
Sources

Publications for Osteogenic Sarcoma

About this section

Articles related to Osteogenic Sarcoma:

(show top 50) (show all 177)
# Title Authors Year
1
Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma. ( 29543677 )
2018
2
Osteogenic Sarcoma of Mandible. ( 28302236 )
2017
3
Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease. ( 28391422 )
2017
4
Chemotherapy in primary osteogenic sarcoma in patients over the age of forty. ( 28214261 )
2017
5
A novel strategy combining magnetic particle hyperthermia pulses with enhanced performance binary ferrite carriers for effective in vitro manipulation of primary human osteogenic sarcoma cells. ( 27442884 )
2016
6
Osteogenic Sarcoma: A 21st Century Review. ( 27630274 )
2016
7
Primary metaplastic carcinoma with osteogenic sarcoma and squamous cell carcinoma differentiation. ( 27584912 )
2016
8
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89). ( 26365289 )
2015
9
Solitary osseous metastasis of rectal carcinoma masquerading as osteogenic sarcoma on post-chemotherapy imaging: a case report. ( 25598687 )
2015
10
Inhibition of c-FLIP by RNAi enhances sensitivity of the human osteogenic sarcoma cell line U2OS to TRAIL-induced apoptosis. ( 25824746 )
2015
11
Osteogenic sarcoma in children and young adults. ( 25028139 )
2014
12
Notch activation as a driver of osteogenic sarcoma. ( 25203324 )
2014
13
Synchronous multifocal osteogenic sarcoma on multimodality imaging including bone scintigraphy. ( 25210291 )
2014
14
Induction of apoptosis by diphenyldifluoroketone in osteogenic sarcoma cells is associated with activation of caspases. ( 24604218 )
2014
15
Mass spectrometric identification of ancient proteins as potential molecular biomarkers for a 2000-year-old osteogenic sarcoma. ( 24475253 )
2014
16
Rare occurrence of bilateral breast and peritoneal metastases from osteogenic sarcoma. ( 23546040 )
2013
17
A case report of osteogenic sarcoma with leprosy. ( 23771385 )
2013
18
Surgical management of incidental renal tumor during excision of retroperitoneal liposarcoma and osteogenic sarcoma. ( 23336645 )
2013
19
Complex biological reconstruction after wide excision of osteogenic sarcoma in lower extremities. ( 23401762 )
2013
20
A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. ( 23540738 )
2013
21
Primary osteogenic sarcoma of the breast: a case report. ( 23997518 )
2012
22
Clinical monitoring in a patient with Friedreich ataxia and osteogenic sarcoma. ( 22752483 )
2012
23
Malignant priapism secondary to osteogenic sarcoma. ( 21330752 )
2011
24
RNAi-mediated COPS3 gene silencing inhibits metastasis of osteogenic sarcoma cells. ( 21436869 )
2011
25
Silencing of HMGA1 expression by RNA interference suppresses growth of osteogenic sarcoma. ( 21573994 )
2011
26
Osteogenic sarcoma in a child with familial expansile osteolysis syndrome: an accidental association? ( 20168251 )
2010
27
Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. ( 20353421 )
2010
28
Induction of mitotic arrest and apoptosis by a novel synthetic quinolone analogue, CWC-8, via intrinsic and extrinsic apoptotic pathways in human osteogenic sarcoma U-2 OS cells. ( 19661327 )
2009
29
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. ( 19670450 )
2009
30
[Effect of dioxin on apoptosis of osteogenic sarcoma cells and regulation on gene expression of insulin-like growth factor binding protein 6]. ( 18724896 )
2008
31
Severe suppression of Frzb/sFRP3 transcription in osteogenic sarcoma. ( 17079093 )
2007
32
High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. ( 17560052 )
2007
33
Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents. ( 17376311 )
2007
34
Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. ( 17513810 )
2007
35
Expression of a novel alternatively spliced UCP-2 transcript in osteogenic sarcoma. ( 16437349 )
2006
36
High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. ( 16857797 )
2006
37
Differential expression and functional characterization of system L amino acid transporters in human normal osteoblast cells and osteogenic sarcoma cells. ( 16827134 )
2006
38
Primary osteogenic sarcoma of the breast. ( 17156481 )
2006
39
Radiation induced osteogenic sarcoma of the maxilla. ( 16042767 )
2005
40
Biology of osteogenic sarcoma. ( 16197719 )
2005
41
Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS). ( 16140185 )
2005
42
Induction of apoptosis by sodium fluorosilicate treatment in human osteogenic sarcoma (HOS) cells. ( 15816563 )
2005
43
Osteogenic sarcoma of the mandible and maxilla: a Canadian review (1980-2000). ( 15841989 )
2004
44
PCR and flow cytometric analysis of paclitaxel-inhibited arylamine N-acetyltransferase activity and gene expression in human osteogenic sarcoma cells (U-2 OS). ( 15015580 )
2004
45
fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence. ( 12660817 )
2003
46
Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation. ( 12538091 )
2003
47
Differential Sensitivity of Taxol-induced Apoptosis in U2OS and SaOS2 Osteogenic Sarcoma Cells. ( 26680929 )
2003
48
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. ( 11992538 )
2002
49
The human homolog of yeast SEP1 is a novel candidate tumor suppressor gene in osteogenic sarcoma. ( 12426100 )
2002
50
Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. ( 11172736 )
2001
Sources

Variations for Osteogenic Sarcoma

About this section

ClinVar genetic disease variations for Osteogenic Sarcoma:

6
(show all 19)
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.49G> T (p.Ala17Ser) single nucleotide variant Pathogenic rs137853008 GRCh37 Chromosome 22, 29130661: 29130661
2 CHEK2 NM_007194.3(CHEK2): c.49G> T (p.Ala17Ser) single nucleotide variant Pathogenic rs137853008 GRCh38 Chromosome 22, 28734673: 28734673
3 CHEK2 NM_007194.3(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh37 Chromosome 22, 29091207: 29091207
4 CHEK2 NM_007194.3(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh38 Chromosome 22, 28695219: 28695219
5 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
6 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
7 TP53 NM_000546.5(TP53): c.475_481dupGCCATGG (p.Ala161Glyfs) duplication Pathogenic rs863223301 GRCh38 Chromosome 17, 7675131: 7675137
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
10 TP53 NM_000546.5(TP53): c.475_481dupGCCATGG (p.Ala161Glyfs) duplication Pathogenic rs863223301 GRCh37 Chromosome 17, 7578449: 7578455
11 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
12 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
13 CHEK2 NM_007194.3(CHEK2): c.319+2T> A single nucleotide variant Likely pathogenic rs587782401 GRCh37 Chromosome 22, 29130389: 29130389
14 CHEK2 NM_007194.3(CHEK2): c.319+2T> A single nucleotide variant Likely pathogenic rs587782401 GRCh38 Chromosome 22, 28734401: 28734401
15 TP53 NM_000546.5(TP53): c.1024C> T (p.Arg342Ter) single nucleotide variant Pathogenic rs730882029 GRCh38 Chromosome 17, 7670685: 7670685
16 TP53 NM_000546.5(TP53): c.1024C> T (p.Arg342Ter) single nucleotide variant Pathogenic rs730882029 GRCh37 Chromosome 17, 7574003: 7574003
17 CHEK2 NM_007194.3(CHEK2): c.170C> T (p.Ser57Phe) single nucleotide variant Uncertain significance rs730881695 GRCh38 Chromosome 22, 28734552: 28734552
18 CHEK2 NM_007194.3(CHEK2): c.170C> T (p.Ser57Phe) single nucleotide variant Uncertain significance rs730881695 GRCh37 Chromosome 22, 29130540: 29130540
19 TSC2 NM_000548.4(TSC2): c.2764_2765delTT (p.Leu922Valfs) deletion other GRCh38 Chromosome 16, 2076512: 2076513

Cosmic variations for Osteogenic Sarcoma:

9
(show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6921292 SMARCA4 bone,NS,osteosarcoma,osteoblastic c.2728A>G p.T910A 19:11021836-11021836 16
2 COSM866 RB1 bone,NS,osteosarcoma,osteoblastic c.1399C>T p.R467* 13:48380062-48380062 16
3 COSM6921291 bone,NS,osteosarcoma,osteoblastic c.2728A>G p.T910A 19:11021836-11021836 16
4 COSM6912846 RYBP bone,NS,osteosarcoma,chondroblastic c.699+1G>A p.? 3:72379039-72379039 15
5 COSM2804274 RPTOR bone,NS,osteosarcoma,chondroblastic c.2911G>A p.V971I 17:80925472-80925472 15
6 COSM1034 RB1 bone,NS,osteosarcoma,chondroblastic c.1499-1G>T p.? 13:48381246-48381246 15
7 COSM6932882 PTCH1 bone,NS,osteosarcoma,chondroblastic c.2183C>T p.T728M 9:95468818-95468818 15
8 COSM6912848 PIK3CB bone,NS,osteosarcoma,chondroblastic c.1064C>G p.A355G 3:138714706-138714706 15
9 COSM302646 KMT2D bone,NS,osteosarcoma,chondroblastic c.15208C>T p.R5070* 12:49024612-49024612 15
10 COSM4591270 KMT2C bone,NS,osteosarcoma,chondroblastic c.2512G>A p.G838S 7:152247922-152247922 15
11 COSM1179669 KMT2C bone,NS,osteosarcoma,chondroblastic c.943G>A p.G315S 7:152273774-152273774 15
12 COSM6506545 KMT2C bone,NS,osteosarcoma,chondroblastic c.2468T>C p.I823T 7:152247966-152247966 15
13 COSM27895 GNAS bone,NS,osteosarcoma,parosteal c.602G>A p.R201H 20:58909366-58909366 15
14 COSM27887 GNAS bone,NS,osteosarcoma,parosteal c.601C>T p.R201C 20:58909365-58909365 15
15 COSM6914869 APC bone,NS,osteosarcoma,chondroblastic c.6517A>G p.K2173E 5:112842111-112842111 15
16 COSM6932881 bone,NS,osteosarcoma,chondroblastic c.2183C>T p.T728M 9:95468818-95468818 15
17 COSM6932883 bone,NS,osteosarcoma,chondroblastic c.2180C>T p.T727M 9:95468818-95468818 15
18 COSM123397 bone,NS,osteosarcoma,chondroblastic c.2530C>T p.R844C 20:58909365-58909365 15
19 COSM6912847 bone,NS,osteosarcoma,chondroblastic c.699+1G>A p.? 3:72379039-72379039 15
20 COSM6932884 bone,NS,osteosarcoma,chondroblastic c.2180C>T p.T727M 9:95468818-95468818 15
21 COSM302647 bone,NS,osteosarcoma,chondroblastic c.16018C>T p.R5340* 12:49024612-49024612 15

Copy number variations for Osteogenic Sarcoma from CNVD:

7 (show top 50) (show all 688)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17390 1 142600000 150300000 Gain Osteosarcoma
2 17391 1 142600000 155000000 Amplification Osteosarcoma
3 39243 10 112373403 112374403 Gain Osteosarcoma
4 39244 10 112373452 112374452 Loss Osteosarcoma
5 41292 10 15522819 15523819 Loss Osteosarcoma
6 41294 10 15581536 15582536 Loss Osteosarcoma
7 46318 10 80680600 80681600 Loss Osteosarcoma
8 46347 10 80806585 80807585 Loss Osteosarcoma
9 58796 11 69623478 69623778 Gain Osteosarcoma
10 58827 11 69805619 69805919 Loss Osteosarcoma
11 60316 11 85062165 85063165 Gain Osteosarcoma
12 60323 11 85134471 85135471 Gain Osteosarcoma
13 62537 12 10955611 10956611 Gain Osteosarcoma
14 62568 12 10980072 10981072 Gain Osteosarcoma
15 62603 12 11027103 11028103 Loss Osteosarcoma
16 63038 12 11366981 11367981 Gain Osteosarcoma
17 63258 12 11668570 11669570 Gain Osteosarcoma
18 63272 12 11686468 11687468 Loss Osteosarcoma
19 64267 12 12569624 12570624 Loss Osteosarcoma
20 64268 12 12573054 12574054 Loss Osteosarcoma
21 64280 12 12586928 12587928 Gain Osteosarcoma
22 64287 12 12597865 12598865 Loss Osteosarcoma
23 64343 12 12687540 12688540 Gain Osteosarcoma
24 64577 12 12982393 12983393 Gain Osteosarcoma
25 64986 12 14117741 14118741 Loss Osteosarcoma
26 64996 12 14185562 14186562 Gain Osteosarcoma
27 64998 12 14245323 14246323 Gain Osteosarcoma
28 65344 12 16046949 16047949 Gain Osteosarcoma
29 65345 12 16049923 16050923 Loss Osteosarcoma
30 65347 12 16051037 16052037 Gain Osteosarcoma
31 65348 12 16051062 16052062 Loss Osteosarcoma
32 65349 12 16054806 16055806 Gain Osteosarcoma
33 65384 12 16430865 16431865 Gain Osteosarcoma
34 65385 12 16433142 16434142 Loss Osteosarcoma
35 65386 12 16436484 16437484 Gain Osteosarcoma
36 65391 12 16463017 16464017 Gain Osteosarcoma
37 65392 12 16466398 16467398 Gain Osteosarcoma
38 65400 12 16603247 16604247 Loss Osteosarcoma
39 65436 12 17462418 17463418 Gain Osteosarcoma
40 65437 12 17462804 17463804 Loss Osteosarcoma
41 65493 12 1815281 1816281 Loss Osteosarcoma
42 65649 12 20337069 20338069 Gain Osteosarcoma
43 65959 12 23459482 23460482 Loss Osteosarcoma
44 65979 12 23822360 23823360 Loss Osteosarcoma
45 66478 12 29963884 29964884 Loss Osteosarcoma
46 66480 12 29986214 29987214 Gain Osteosarcoma
47 66482 12 30002256 30003256 Loss Osteosarcoma
48 66483 12 30014548 30015548 Loss Osteosarcoma
49 66485 12 30029899 30030899 Loss Osteosarcoma
50 67171 12 37173408 37174408 Loss Osteosarcoma
Sources

Expression for Osteogenic Sarcoma

About this section
Search GEO for disease gene expression data for Osteogenic Sarcoma.
Sources

Pathways for Osteogenic Sarcoma

About this section

Pathways related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
BRCA1 Pathway 64
Show member pathways
 11.35 CHEK2 RB1 TP53
2
Integrated Cancer Pathway 1
10.79 CHEK2 RB1 TP53
3
Inhibition of Ribosome Biogenesis by p14(ARF) 64
10.66 RB1 TP53
4
LncRNA-mediated mechanisms of therapeutic resistance 1
9.88 HOTAIR TP53 UCA1
5
PLK3 signaling events 1
9.85 CHEK2 TP53
Sources

GO Terms for Osteogenic Sarcoma

About this section

Cellular components related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 CHEK2 RB1 TP53

Biological processes related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 CHEK2 TP53
2 replicative senescence GO:0090399 8.96 CHEK2 TP53
3 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 8.8 CHEK2 SOX4 TP53
Sources

Sources for Osteogenic Sarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....